Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice
Open Access
- 17 September 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Abstract
Key Points: Glucosuria is a proxy for adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors. Patients with glucosuria during SGLT2 inhibitor prescriptions have lower risk of mortality, heart failure, and kidney failure. Background: Medication nonadherence contributes to the efficacy–effectiveness gap in real-world practice. Glucosuria, routinely measured on urinalysis, may serve as an objective proxy for assessing medication adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of medications that reduce the risks of kidney disease, heart failure, and mortality. Methods: We leveraged 2 cohorts from the Optum Labs Data Warehouse real-world data (2014–2023): cohort 1 included 3987 patients with SGLT2 inhibitor pharmacy claims and a urinalysis performed both before and during active fill periods; cohort 2 included 45,711 patients prescribed SGLT2 inhibitors with urinalysis performed within 6 months after initiation. Glucosuria was defined as urine glucose 2+ or greater. Cohort 2 was followed for a mean of 3.3 years for all-cause mortality, heart failure hospitalization, and kidney failure; fractures were used as a negative control outcome. Results: In cohort 1, SGLT2 inhibitor use (versus no use) was associated with 18.1-fold higher odds of glucosuria (95% confidence interval [CI], 16.4 to 20.0), adjusted for diabetes status. In cohort 2, 26,657 (58%) had glucosuria within 6 months of SGLT2 inhibitor initiation, suggesting adherence. After inverse probability of treatment weighting, glucosuria was associated with lower risks of all-cause mortality (hazard ratio [HR], 0.78; 95% CI, 0.73 to 0.83), heart failure hospitalization (HR, 0.87; 95% CI, 0.78 to 0.98), and kidney failure (HR, 0.73; 95% CI, 0.58 to 0.91) compared with no glucosuria. No association was observed with fractures (HR, 1.00; 95% CI, 0.95 to 1.06). Conclusions: Glucosuria was associated with SGLT2 inhibitor adherence and, among patients prescribed SGLT2 inhibitors, is associated with reductions in risks of all-cause mortality, heart failure, and kidney failure.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK115534)
- National Heart, Lung, and Blood Institute (K24HL1155861)
This publication has 23 references indexed in Scilit:
- SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsThe Lancet, 2022
- Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trialsHeart Rhythm, 2021
- Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2020
- Self-reported Medication Adherence and CKD ProgressionKidney International Reports, 2018
- A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitusEndocrine, 2017
- Improving Medication Adherence in Cardiometabolic DiseaseJACC, 2017
- How to Screen for Non-Adherence to Antihypertensive TherapyCurrent Hypertension Reports, 2016
- Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort studyClinical and Experimental Nephrology, 2016
- The “Efficacy-Effectiveness Gap”: Historical Background and Current ConceptualizationValue in Health, 2016
- Adherence with statin therapy in elderly patients with and without acute coronary syndromesACC Current Journal Review, 2002